Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.

被引：0
|
作者：
Flaherty, Lawrence E.
Moon, James
Atkins, Michael B.
Tuthill, Ralph
Thompson, John A.
Vetto, John T.
Haluska, Frank G.
Pappo, Alberto S.
Sosman, Jeffrey Alan
Redman, Bruce G.
Ribas, Antoni
Kirkwood, John M.
Sondak, Vernon K.
机构：
[1] Wayne State Univ, Detroit, MI USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Cleveland Clin, Cleveland, OH 44106 USA
[5] Seattle Canc Care Alliance, Seattle, WA USA
[6] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[7] ARIAD Pharmaceut, Cambridge, MA USA
[8] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[9] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[10] Univ Michigan, Ann Arbor, MI 48109 USA
[11] Univ Calif Los Angeles, Los Angeles, CA USA
[12] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[13] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8504
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CNS metastases as a site of progression on SWOG intergroup study S0008: A phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 (BCT) versus high-dose interferon (HDI) in patients with high-risk melanoma
    Samlowski, Wolfram E.
    Moon, James
    Witter, Merle
    Atkins, Michael B.
    Kirkwood, John M.
    Othus, Megan
    Ribas, Antoni
    Sondak, Vernon K.
    Flaherty, Lawrence E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
    Flaherty, Lawrence E.
    Othus, Megan
    Atkins, Michael B.
    Tuthill, Ralph J.
    Thompson, John A.
    Vetto, John T.
    Haluska, Frank G.
    Pappo, Alberto S.
    Sosman, Jeffrey A.
    Redman, Bruce G.
    Moon, James
    Ribas, Antoni
    Kirkwood, John M.
    Sondak, Vernon K.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3771 - +
  • [3] Adjuvant therapy of high-risk melanoma: The role of high-dose interferon alpha-2b
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, T
    Borden, E
    Blum, R
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 251 - 257
  • [4] Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.
    Lian, Bin
    Cui, Chuanliang
    Si, Lu
    Yang, Yue
    Wu, Di
    Li, Ke
    Wang, Xuan
    Chi, Zhihong
    Sheng, Xinan
    Mao, Lili
    Tang, Bixia
    Yan, Xieqiao
    Li, Siming
    Bai, Xue
    Zhou, Li
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase II trial of bevacizumab and high-dose interferon alpha-2b in metastatic melanoma
    Grignol, V. P.
    Olencki, T.
    Taylor, C.
    Kibler, A.
    Kefauver, C.
    Wei, L.
    Walker, M. J.
    Chen, H. X.
    Kendra, K. L.
    Carson, W. E., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma.
    Grossmann, Kenneth F.
    Othus, Megan
    Tarhini, Ahmad A.
    Patel, Sapna Pradyuman
    Kirkwood, John M.
    Moon, James
    Sondak, Vernon K.
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.
    Si, Lu
    Wang, Xuan
    Kong, Yan
    Lian, Bin
    Chi, Zhi Hong
    Cui, Chuan Liang
    Sheng, Xi Nan
    Mao, Li Li
    Tang, Bi Xia
    Li, Si Ming
    Yan, Qiao Xie
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [9] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [10] Randomized Phase III Study of 1 Month Versus 1 Year of Adjuvant High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
    Pectasides, Dimitrios
    Dafni, Urania
    Bafaloukos, Dimitrios
    Skarlos, Dimosthenis
    Polyzos, Aristidis
    Tsoutsos, Dimosthenis
    Kalofonos, Haralambos
    Fountzilas, George
    Panagiotou, Petros
    Kokkalis, George
    Papadopoulos, Othon
    Castana, Ourania
    Papadopoulos, Stefanos
    Stavrinidis, Elias
    Vourli, Georgia
    Ioannovich, John
    Gogas, Helen
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 939 - 944
12345